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Objective. To describe trends in the use of percutaneous coronary intervention (PCI)
following the COURAGE trial, which found that medical therapy is as effective as PCI
for patients with stable angina.
Data Sources. We used the National Hospital Discharge Survey; inpatient and outpa-
tient discharge data from Florida, Maryland, and New Jersey; and the English Hospital
Episode Statistics database.
Study Design. We report trends in PCI volume by diagnosis (stable angina vs. unsta-
ble angina or AMI) before and after publication of the COURAGE trial.
Principal Findings. The number of PCIs in patients without a diagnosis of AMI or
unstable angina in Florida, Maryland, and New Jersey declined from 48,000 in 2006 to
40,000 in 2008 (17 percent). There was no change in the number of PCIs in patients
with a diagnosis of AMI. We observed similar patterns in U.S. community hospitals.
PCI volume did not decline in England.
Conclusions. PCI volume declined after publication of the COURAGE trial. The
experience of the COURAGE trial suggests that comparative effectiveness research
can lead to cost-saving changes in medical practice patterns. However, there are many
patients with stable coronary disease who continue to receive PCI post-COURAGE.
Key Words. Medical decision making, access, demand, utilization of services,
technology adoption, diffusion, use
When a major study finds that a widely used medical treatment is no better
than a less expensive alternative, do physicians stop using it? The premise
behind comparative effectiveness research is that expensive treatments often
diffuse into clinical practice without evidence that they are better than existing
therapies (Chandra, Jena, and Skinner 2011). Policy makers hope that compar-
ative effectiveness studies will identify ineffective but costly treatments, lead-
ing to cost savings. However, it remains unclear how studies that report
“negative” results influence medical treatment patterns. The same factors that
promote rapid adoption of new medical technologies—fee-for-service reim-
bursement, third-party payment, etc. (Emanuel and Fuchs 2008)—may retard
the abandonment of widely used technologies found to be ineffective.





Percutaneous coronary intervention (PCI) is an invasive procedure to
open clogged coronary arteries. Medicare spent over $5 billion on PCIs in
2005 (Committee on Finance, United States Senate 2010). In 1999 the Depart-
ment of Veterans Affairs initiated a multimillion dollar study, the COURAGE
trial, to compare PCI and medical therapy versus a regimen of medical ther-
apy alone in patients with stable angina. The study, which was published in
April 2007 in the New England Journal of Medicine (Boden et al. 2007), found
that the treatments were equivalent in terms of survival time and heart attack
risk.
Articles in the Wall St. Journal (Weinstein 2010) and the Washington Post
(Brown 2012) used the COURAGE trial to illustrate the challenges facing
policy makers who want to rein in costs using comparative effectiveness
research. However, there has been little research on the impact of the COUR-
AGE trial on practice patterns. In this study, we assess trends in the use of PCI
by indication following publication of the COURAGE trial.
TECHNOLOGICAL ABANDONMENT
Many technologies diffuse into clinical practice without evidence that they are
effective. David Eddy (1993) summarized the prevailing mindset with respect
to new technologies as: “When in doubt, do it.” Subjecting establishedmedical
practices to trials can identify treatments that are no better than less expensive,
less invasive alternatives. Prasad, Cifu, and Ioannidis (2012) reviewed all stud-
ies published in the New England Journal of Medicine in 2009 and found that
reversals—studies reporting negative findings for established medical prac-
tices—are common, constituting nearly half of studies that evaluated estab-
lished practices. Presumably, the number of reversals will increase as the
newly formed Patient-Centered Outcomes Research Institute begins to fund
comparative effectiveness studies.
Many observers are pessimistic about the potential impact of studies
reporting negative results. Once established, treatments may be difficult to
dislodge. The same factors that promote rapid diffusion of new health care
technologies—fee-for-service reimbursement, third-party payment, and the
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technological imperative in modern medicine (Phelps 1992; Emanuel and
Fuchs 2008)—may retard the abandonment of widely used technologies
found to be ineffective. Treatment decisions may be subject to inertia, and, in
some cases, entire specialties are defined by the delivery of a specific technol-
ogy (Schroeder and Showstack 1979). Specialists have a “pro-intervention
bias” (Timbie et al. 2012) and may ignore “inconveniently negative” results
(Lenzer 2012).
A handful of studies have examined the impact of comparative effective-
ness research studies reporting negative results. Examples of technologies
where the use of the treatment continued unabated after the publication of
negative results include percutaneous coronary angioplasty (PCI) in patients
with occluded infarct-related arteries identified more than 24 hours postmyo-
cardial infarction (Deyell et al. 2011), calcium channel blockers, and angioten-
sin-converting enzyme inhibitors as first-line treatments for patients with
hypertension (Stafford et al. 2006), radiotherapy in older women with smal-
ler, early-stage breast tumors (Soulos et al. 2012), and directional coronary
atherectomy (Omoigui et al. 1998). These cases stand in stark contrast to
instances where positive results for new technologies have led to rapid adop-
tion, in some cases even before the results have been published (Gross et al.
2000; Giordano et al. 2006).
In some cases negative results influence practice patterns. Trials report-
ing negative results for intermittent positive pressure breathing therapy (Duffy
and Farley 1992), high-dose chemotherapy/hematopoietic cell transplants for
women with breast cancer (Howard et al. 2011), PCI for patients with stable
angina (Howard and Shen 2012), and arthroscopic surgery for osteoarthritis of
the knee (Howard, Brophy, and Howell 2012) have led to reductions in the
use of these procedures.
THE COURAGETRIAL
Chronic stable angina is characterized by chest pain during exertion caused
by a narrowing of the coronary arteries. Treatment options include revascular-
ization via PCI or a low-cost regimen of medical therapy and lifestyle modifi-
cation. PCI entails cardiac catheterization, use of balloon angioplasty to
mechanically open the artery, and, in most cases, placement of a stent to
maintain blood flow. The Department of Veterans Affairs–sponsored Clinical
Outcomes Using Revascularization and Aggressive Drug Evaluation
(COURAGE) trial randomized 2,287 patients with stable angina to receive
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optimal medical therapy alone or PCI plus medical therapy between 1999
and 2004. The main finding from the COURAGE trial was that there was no
difference between treatment arms in the incidence of mortality or acute myo-
cardial infarction (AMI) (Boden et al. 2007). The results “shook the world of
cardiology” (Weinstein 2010).
A subsequent analysis found that although patients in the PCI arm expe-
rienced earlier resolution of symptoms, quality of life was no different after
3 years (Weintraub et al. 2008a). Lifetime costs for stable ischemic heart dis-
ease patients treated with PCI are over $9,000 higher than for patients treated
with optimal medical therapy alone (Weintraub et al. 2008b).
Like all trials, the COURAGE trial had limitations, and cardiologists
disagree on the relevance of the COURAGE trial to clinical practice. Some
cardiologists criticized the trial on the grounds that the inclusion criteria were
too restrictive, rates of compliance with medical therapy were much higher
than is typically observed in routine practice, the trial was underpowered, the
trial was performed before the widespread diffusion of drug-eluting stents,
which are associated with better outcomes, and cardiologists should have
implanted more stents in patients randomized to PCI with multivessel disease
(Kereiakes et al. 2007). Other cardiologists believe that the trial has important
and wide-ranging implications for practice.
Prominent cardiologists perceive that fee-for-service reimbursement is a
major obstacle to implementing the COURAGE trial results. Peterson and
Rumsfeld (2008) write: “[The COURAGE trial] underscores a major chal-
lenge to clinicians—how to successfully execute a strategy of optimal medical
therapy in a health care system that provides strong financial incentives for
PCI but few rewards for careful management of medications.” The principal
investigator of the COURAGE trial, Dr. William Boden, echoed these senti-
ments (Weinstein 2010): “What’s going to continue to drive practice is reim-
bursement.” We are unaware of changes to insurers’ coverage polices around
2007, COURAGE related or otherwise, that would have materially affected
PCI rates.
Several studies have examined the impact of the COURAGE trial on
practice patterns. Ahmed et al. (2011), using data from 10 hospitals in Maine,
NewHampshire, and Vermont, found that there was an approximately 25 per-
cent decline in PCI volume among patients with stable angina following publi-
cation of the COURAGE trial. The hospitals are all nonprofit and participate
in a voluntary cardiac disease registry. Borden et al. (2011) found that there
was only a small (1.2 percentage point) increase in the proportion of patients
with stable coronary disease undergoing PCI who received optimal medical
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therapy prior to PCI. They did not assess trends in the volume of PCIs among
patients with stable coronary disease. Although both Ahmed et al. and
Borden et al. provide evidence on the impact of the COURAGE trial, neither
reports trends in the use of PCI in a large, representative sample of hospitals.
METHODS
Overview
We compare trends in the use of PCI among patients with diagnoses similar to
those of patients in the COURAGE trial with trends in the use of PCI with
diagnoses that would have made them ineligible for participation in COUR-
AGE. We use three datasets. Note that only one of the four datasets we use to
identify the impact of the COURAGE trial is a sample. The other datasets
capture the universe of discharges in their respective regions or health sys-
tems, and so estimates of the number of PCIs in each year are not subject to
sampling variation.
Data Sources
National Hospital Discharge Survey (NHDS). The NHDS is a random sample of
hospital discharges in U.S. community hospitals. The sample size ranges
between 120,000 and 300,000 discharges annually.
We identified patients undergoing PCI using International Classification
of Diseases, Volume 9 (ICD-9), procedure codes 36.01, 36.02, 36.05, 36.06,
36.07, and 36.09. We grouped patients into two mutually exclusive categories.
The “Other Diagnoses, Elective” group includes patients without a diagnosis
of AMI (ICD-9 code 410.X) where the admission type was recorded as “Elec-
tive.” The NHDS, unlike the other databases we use, includes a variable indi-
cating whether the admission was “Elective,” “Urgent,” or an “Emergency.”
Criteria follow inpatient billing criteria and are described in Buie et al. (2010).
The “AMI and Other Diagnoses, Non-Elective” group includes all patients
with a diagnosis of AMI and patients with other diagnoses with an “urgent” or
“emergency” admission. Procedure counts were weighted to produce nation-
ally representative estimates.
Florida, Maryland, and New Jersey. We tracked trends in PCI volume in Florida,
Maryland, and New Jersey using the State Inpatient Discharge and State
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Ambulatory Surgery databases. These databases capture 100 percent or close
to 100 percent of hospital discharges and hospital-based outpatient surgical
procedures, depending on the state.
We identified patients undergoing PCI in the State Inpatient Discharge
databases using the ICD-9 procedure codes listed above. We also used Cur-
rent Procedural Terminology codes 92973, 92980, 92981, 92982, 92983,
92984, 92985, 92996, G0290, G0291, and S2220 to identify patients under-
going PCI in the State Ambulatory Surgery database. We also specifically
identified patients who received drug-eluting stents using ICD-9 procedure
code 36.07.
We grouped patients into three categories: (1) stable angina (records
excluding ICD-9 codes 410.X [AMI] and 411.1 [unstable angina]); (2) unstable
angina (records with ICD-9 code 411.1); and (3) AMI (records with ICD-9
code 410.X). Patients in the first group include those with a diagnosis of stable
angina or with a general ischemic heart disease diagnosis code, but no diagno-
sis of AMI or unstable angina. Pre-COURAGE, patients with stable angina
accounted for one third of all PCI procedures (Peterson and Rumsfeld 2008),
and it is likely that a large share of patients in the stable angina group would
have satisfied the COURAGE inclusion criteria.
English Hospitals. The Hospital Episode Statistics is a census of discharges
from English National Health Service hospitals. We identified PCIs using
ICD-10 codes K49.X and K75.X. We grouped patients based on diagnosis
using codes I21.X (AMI) and I20.0 (unstable angina). English cardiologists
are salaried. Hospitals are paid under fee-for-service–like reimbursement
scheme, “Payment by Results.”
Analysis
We describe trends in PCI volume by indication and test whether the propor-
tion of patients undergoing PCI with stable angina (or, alternatively, patients
without a diagnosis of unstable angina or AMI) has changed over time.
The rationale for this analysis is as follows.
Let Nt be the number of patients with stable angina in period t, nt be the
number who receive a PCI in period t, and at be a parameter describing treat-
ment practices such that nt = a
tNt. Our hypothesis is that the treatment thresh-
old for patients with stable angina is different pre- and post-COURAGE:
aPRE > aPOST.
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If we observed all patients with stable angina, Nt, including those who
did not receive treatment, we could estimate aPRE and aPOST directly. As an
alternative, we make use of the information contained in PCI volume for
patients with unstable angina or AMI. The equation definining the relation-
ship between the number of patients with these conditions and the number
receiving PCI is mt = cMt, which is analogous to nt = a
tNt. Also, assume that
Nt = dMt, which describes the relationship between the total number of
patients with stable angina and the number with unstable angina or AMI.
The number of PCIs in patients with stable angina as a fraction of total
PCIs is nt  nt þ mtð Þ. By substituting nt = aNt, mt = cMt, and then mt = cMt,
we have:
ht ¼ nt
nt þ mt ¼
atdc1
atdc1 þ 1 :
Testing hPRE = hPOST amounts to a test of aPRE = aPOST under the
assumptions that the relationships between the number of patients with unsta-
ble angina or AMI and PCI use (c) and the number of patients with unstable
angina or AMI and stable angina (d) have remained stable over time. These
assumptions are not literally true. The prevalence of coronary artery disease
has declined over time (Centers for Disease Control and Prevention [CDC]
2011) due to changes in risk factors such as cholesterol levels, smoking rates,
and systolic blood pressure levels (Ford et al. 2007;Wijeysundera et al. 2010).
The introduction of drug-eluting stents and other new technologies has altered
physicians’ approaches for treating patients with unstable coronary artery dis-
ease (Epstein et al. 2011). However, none of these changes is occuring so rap-
idly as to impart substantial bias over the short time frame over which we are
examining trends in PCI use.
We test hPRE = hPOSTusing a t-test for proportions. Note that this analy-
sis accounts for secular trends in the use of PCI; it does not assume that Nt and
Mt are constant over time.
RESULTS
Collectively, the datasets include observations for 652,000 PCIs. There was
little change in the demographic characteristics of patients undergoing PCI
(see Appendix Table).
Figure 1 presents nationally representative trends in quarterly PCI vol-
ume from the NHDS. The NHDS included observations for 46,760 PCIs
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over the period 2001–2008. Trends are presented relative to volume in the first
quarter of 2001 (= 1 on the y-axis) to facilitate comparison between groups.
The vertical dashed line indicates the publication date of the COUR-
AGE trial: April 12, 2007. The markers on either side of the dashed line indi-
cate relative PCI volume in the first and second quarters of 2007. The graph
shows that PCI volume declined between the first and second quarters. It does
not indicate whether the decline began before or after April 12.
PCI volume in the Other Diagnoses, Elective group, increased in 2001
and 2002, plateaued between 2003 and 2006, and declined rapidly following
publication of the COURAGE trial. There was also a decrease in PCI volume
in late 2007 among patients in the AMI and Other Diagnosis, Nonelective
group.
Figure 2 presents PCI volume trends from the State Inpatient Discharge
and State Ambulatory Surgery databases for Florida, Maryland, and New
Jersey. There are observations for 361,364 PCIs. Of these, 219,169 were
performed in Florida, 51,435 in Maryland, and 91,993 in New Jersey. Trends
are presented relative to volume in the first quarter of 2008 (= 1 on the y-axis).
PCI volume in all three groups declined immediately following publication of
the COURAGE trial. PCI volume in AMI patients rebounded to pre-COUR-
AGE levels, whereas volume in patients with diagnoses of unstable angina or
stable angina and other diagnoses remained below 2006 levels.
A September 2006 persentation at an international cardiology confer-
ence (Camenzind, Steg, and Wijns 2006) raised concerns about the safety of
drug-eluting stents. Although cardiologists could have substituted bare metal
stents, and subsequent studies reaffirmed the benefits of drug-eluting stents
Figure 1: Quarterly PCI Volume by Indication, U.S. Hospitals
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(Malenka et al. 2008; James et al. 2009), the findings may have temporarily
depressed demand for PCI. To help disentangle the impact of the stent study
and the COURAGE trial, Figure 3 reports trends in PCI volume (all diagno-
ses) and the percentage of PCIs in which patients received a drug-eluting stent.
PCI volume is displayed relative to levels in the first quarter of 2006 so that
PCI and drug-eluting stent trends are displayed on a common scale. We focus
on the period 2006–2007 to isolate the impact of each study. Use of drug-elut-
ing stents, depicted by the dashed line with hollow triangles, declined between
the third and fourth quarters of 2006, coincident with the release of the drug-
eluting stent abstract. Use continued to decline through 2007, but the rate of
Figure 2: Quarterly PCI Volume by Indication, United States (FL,MD, NJ)
Figure 3: Use of DES and PCI Volume Relative to Q1 2006 by Indication,
United States (FL,MD, NJ)
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the decline had already started to slow by the time the COURAGE trial was
published. Overall PCI volume declined prior to the release of the drug-elut-
ing stent abstract but did not decline again until the COURAGE trial was pub-
lished.
Figure 4 displays trends in PCI volume in English hospitals. The Hospi-
tal Episode Statistics database included observations for 243,202 PCIs over
the period 2006 through the first quarter of 2009. There was a slight drop in
PCI volume among patients with stable angina/other diagnoses following
publication of the COURAGE trial; it does not appear that the trial had a
long-lasting effect on volume.
Table 1 presents relative trends in PCI volume by indication. According
to the NHDS, the number of PCIs in patients without a diagnosis of AMI or
unstable angina and whose procedures were deemed elective declined from
137,000 in 2006 to 84,000 in 2008 (39 percent). The number of PCIs in
patients with a diagnosis of AMI or whose procedures were deemed nonelec-
tive declined from 500,000 in 2006 to 439,000 in 2008 (12 percent).
For the purposes of assessing the impact of the COURAGE trial in the
other datasets, we compare trends among patients with stable angina/other
diagnoses and AMI. According to the State Inpatient Discharge and State
Ambulatory Surgery databases, the number of PCIs in patients without a diag-
nosis of AMI or unstable angina in Florida, Maryland, and New Jersey
declined from 48,000 in 2006 to 40,000 in 2008 (17 percent). The number of
PCIs in patients with a diagnosis of AMI did not decline.
PCI volume in England among patients with stable angina/other diag-
noses increased slightly, from 36.8 to 37.0 thousand. Procedure volume
Figure 4: Quarterly PCI Volume by Indication, England
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among patients with a diagnosis of AMI increased from 14,000 to 18,000
(4 percent).
The last column of Table 1 presents the proportion of PCIs performed
in patients with stable angina/other diagnoses in 2006 and 2008. In each case,
the decline in the proportion was significant at the 0.001 percent level. The
decline in the proportion in England reflects the increase in the use of PCIs in
patients with AMI rather than a decline in patients with stable angina/other
diagnoses.
DISCUSSION
The number of PCIs performed in the United States declined after 2006. Our
best estimate, based on combined inpatient and outpatient data, is that PCI
use declined by 17 percent in the United States among patients without diag-
noses of AMI or unstable angina. Seasonality in PCI use, secular trends in the
number of patients with ischemic heart disease, and the release of other studies
on the effectiveness of PCI (e.g., Camenzind, Steg, and Wijns 2006) make it
Table 1: Change in PCIs by Indication, 2006–2008
PCIs
No. (1,000s) [Rate per 100 K persons age ≥45]
Elective Nonelective Proportion
United States: NHDS
2006 137 [116] 500 [420] 0.22
2008 84 [70] 439 [369] 0.16*
Change 54 (39%) 61 (12%)
Stable Angina AMI Proportion
FL,MD, andNJ: SID and SASD
2006 48 [178] 30 [112] 0.61
2008 40 [147] 30 [112] 0.57*
Change 8 (17%) 0 (0%)
England hospital episode statistics
2006 37 [171] 14 [63] 0.73
2008 37 [172] 18 [82] 0.68*
Change 0 (1%) 4 (31%)
*The difference in proportions between 2006 and 2008 is significant at the 0.001 level.
AMI, acute myocardial infarction; NHDS, national hospital discharge survey; PCI, percutaneous
coronary intervention; SASD, state ambulatory surgery data; SID, state inpatient discharge data.
Trends in PCI Volume 163
difficult to precisely identify the impact of the COURAGE trial on PCI use.
However, several factors suggest that COURAGE contributed to declining
PCI use. First, there was a large decrease in use immediately following publi-
cation of the COURAGE trial on April 12, 2007. Second, use of PCI for
angina declined while use for AMI remained at pre-COURAGE levels.
We were surprised that use of PCI for patients with a diagnosis of unsta-
ble angina declined post-COURAGE. Patients with unstable angina would
not have been candidates for inclusion in COURAGE. We speculate that
either some cardiologists may have extrapolated the results of the COUR-
AGE trial to other patient groups or, more likely, diagnostic coding on claims
was insufficiently specific to distinguish between stable and unstable angina.
Our inability to observe patients with stable angina who do not receive
PCI precludes use of regression models to assess the statistical significance of
changes in PCI volume or measurement of trends in the use of alternatives to
PCI. Use of claims data could potentially circumvent this problem, but the
alternatives to PCI are so widely used that we doubt it would be possible to
identify patients who considered but did not receive PCI post-COURAGE.
Our statistical analysis assumes that publication of the COURAGE trial did
not affect use of PCI among patients with unstable angina or AMI. This is a
strong assumption, given the trendlines in Figures 1 and 2, but, to the extent
that COURAGE depressed PCI use in this group, the analysis would be
biased against finding a significant result because we assume these declines
reflect a secular trend.
Stable angina is rarely recorded as a diagnosis in inpatient discharge
data. We tried to identify patients for whom the COURAGE results were rele-
vant by identifying patients without a diagnosis of AMI or unstable angina or,
in the NHDS, patients whose procedure was classified as “elective.” Patients
who met these criteria were included in the Stable Angina category. The pro-
portion of patients in the category varied across datasets, reflecting differences
in geographic coverage and care setting (inpatient only vs. inpatient and out-
patient). The Stable Angina category includes a mix of patients, only some of
whom would have met the COURAGE inclusion criteria. Pre-COURAGE,
patients with stable angina accounted for one third of all PCI procedures
(Peterson and Rumsfeld 2008). On the basis of these data, we suspect that
the COURAGE trial is relevant for many, though not all, of the patients in
our Stable Angina group. Our results overstate the proportion of patients with
stable angina but, because of misclassification, understate the impact of
the COURAGE trial on practice patterns.
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The share of PCIs performed on an outpatient basis in Florida, Mary-
land, and New Jersey was 1.9 percent in 2006, 4.3 percent in 2007, 7.9 percent
in 2008, and 7.9 percent in 2009. Excluding patients with AMI or unstable
angina, the share increased from 3.4 to 24.1 percent over this period. The
NHDS includes inpatient PCIs only, and so these results should be viewed
with caution. However, it is unlikely that the sharp decline in PCI volume
observed in 2007 can be fully explained by the shift in care settings. To the best
of our knowledge, PCI was not performed on an outpatient basis in England
during the study period.
PCI rates did not decline in England following COURAGE. Pre-
COURAGE, PCI rates were lower in England due to differences in the preva-
lence of heart disease (Banks et al. 2006) and treatment patterns (Mark et al.
1994; Adams et al. 1998; Yusuf et al. 1998; TECH Research Network 2001).
However, over half the patients undergoing PCI in the United Kingdom
receive the procedure for stable angina and other forms of stable coronary dis-
ease (NHS Information Center 2007), suggesting that there are unexploited
opportunities to substitute medical therapy for PCI. The impact of COUR-
AGE on PCI volume in England may have been dampened by capacity con-
straints. If demand exceeds capacity, then a shift from PCI to medical therapy
would show up as a decline in waiting times rather than a change in observed
procedure volume.
Prominent cardiologists were pessimistic about the potential impact of
the COURAGE trial in the United States given the incentives facing cardiolo-
gists. Other cardiologists argued that the trial lacked external generalizability
and relevance in an era of widespread use of drug-eluting stents. The experi-
ence of the COURAGE trial highlights the difficulty of designing trials that
will influence clinical practice in the event they find a negative result,
especially in fields where technology and practice are constantly evolving.
This issue has bedeviled trials of PCI. Jones (as quoted in Park [2013]) notes:
As long as you continue to innovate in a way that, at face value, looks to be an
improvement, the believers can always step out from under the weight of negative
clinical experience by saying that the research necessarily applies to an earlier state
of medical technology.
Another trial testing PCI versus medical therapy alone, The Interna-
tional Study of Comparative Health Effectiveness with Medical and Invasive
Approaches, is ongoing and will address some of the shortcomings of the
COURAGE trial.
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Comparative effectiveness trials such as COURAGE have important
implications for health care spending. Lifetime costs for stable ischemic heart
disease patients treated with PCI are over $9,000 higher than for patients
treated with optimal medical therapy alone (Weintraub et al. 2008b). If
medical practice patterns respond asymetrically to positive and negative
evidence—physicians adopt new treatments based on “positive” results but do
not abandon existing ones following “negative” studies—then comparative
effectiveness research is unlikely to reduce spending and may very well lead
to increased costs.
We find that use of PCI declined following publication of the
COURAGE trial. The rate of decline was largest among the diagnostic
groups that include the types of patients who were enrolled in the
COURAGE trial. The experience of the COURAGE trial suggests that
comparative effectiveness research can lead to cost-saving changes in
medical practice patterns. However, our results and audit studies (Chan
et al. 2011) indicate that there may be additional opportunities to substi-
tute medical therapy for PCI.
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